When was Molecular Partners founded?

Molecular Partners was founded in 2004.

Where is Molecular Partners located?

Molecular Partners is located in Zurich, Switzerland .

Who is the current CEO of Molecular Partners?

Christian Zahnd and Patrick Amstutz are the current CEO of Molecular Partners.

When was the latest funding round of Molecular Partners?

Molecular Partners's latest funding round was on Jul 2020.

Where does Molecular Partners rank among its competitors?

Molecular Partners ranks 117 amongst 3307 active competitors.

Who are the top competitors of Molecular Partners?

Molecular Partners' top competitors are Jazz Pharmaceuticals, Moderna and BeiGene.

Molecular Partners - 2025 Company Profile, Funding & Competitors

Molecular Partners is a public company based in Zurich (Switzerland), founded in 2004 by and . It operates as a Developer of therapeutic solutions for treating multiple diseases. Molecular Partners has raised $59.9M in funding from Index Ventures. The company has 3307 active competitors, including 1148 funded and 780 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and BeiGene.

Company Details

Developer of therapeutic solutions for treating multiple diseases. The company specializes in developing DARPin that is designed with ankyrin repeat proteins-based therapies for the treatment of severe or life-threatening diseases with an initial focus on oncology and ophthalmology. MP0250 is their most advanced oncology candidate and can be used for the treatment of solid tumors and hematological malignancies.

Key Metrics

Founded Year

2004

Location

Zurich, Switzerland

Stage

Public

Total Funding

in 3 rounds

Latest Funding Round

Investors

Index Ventures & 5 more

Ranked

117^th among

Similar Companies

Jazz Pharmaceuticals &

Exit Details

Public

Get your free copy of Molecular Partners's company profile

Molecular Partners has raised a total funding of $59.9M over 3 rounds. Its first funding round was on Aug 14, 2007.

Molecular Partners has 6 institutional investors including Index Ventures, EW Healthcare Partners and Johnson & Johnson Innovation 鈥� JJDC.

Here is the list of recent funding rounds of Molecular Partners:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
Jul 2020	Undisclosed	Post IPO	7758374	6450920	-
Dec 15, 2009	$44.5M	Series B	1307688	4068161	Index Ventures, Johnson & Johnson Innovation 鈥� JJDC, and
Aug 14, 2007	$15.4M	Series A	4863200	2777348	Index Ventures, BB Biotech Ventures, and

Access funding benchmarks and valuations. Sign up today!

View details of Molecular Partners's funding rounds and investors

The founders of Molecular Partners are and . and are the CEO of Molecular Partners.

View details of Molecular Partners's Founder profiles and Board Members

Top competitors of Molecular Partners include Jazz Pharmaceuticals, Moderna and BeiGene. Here is the list of Top 10 competitors of Molecular Partners, ranked by 秘密研究所 score :

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of therapeutics for cancer and neurological disorders	$265M	InterWest Partners, Investor Growth Capital听&补尘辫;听	85/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Flagship Pioneering, Wellington听&补尘辫;听	85/100
3rd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	T. Rowe Price, Temasek听&补尘辫;听	84/100
4th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Vivo Capital, HBM Partners听&补尘辫;听	82/100
5th	Adaptive Biotechnologies 2009, Seattle (United States), Public	Provider of clinical diagnostics, and drug discovery for immune diseases	$419M	Foresite Capital, Orbimed听&补尘辫;听	82/100
6th	Recursion 2013, United States, Public	R&D based company focused on manufacturing of drugs for multiple therapeutic areas	$452M	HTIF, Menlo Ventures听&补尘辫;听	81/100
7th	Incyte 1991, Wilmington (United States), Public	Developer of small molecules for the treatment of different cancer and skin diseases	-	Tekla Capital Management, Ridgeback Capital Management听&补尘辫;听	78/100
8th	Revolution Medicines 2014, Redwood City (United States), Public	Developer of therapies for treating cancer	$181M	Vivo Capital, Deerfield听&补尘辫;听	78/100
9th	Dynavax 1996, Berkeley (United States), Public	Developer of products to prevent and treat infectious and inflammatory diseases and cancer	$73.9M	InterWest Partners, Hercules Capital听&补尘辫;听	77/100
10th	Blueprint Medicines 2008, Cambridge (United States), Public	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Ridgeback Capital Management, Foresite Capital听&补尘辫;听	76/100
117th	2004, Zurich (Switzerland), Public	Developer of therapeutic solutions for treating multiple diseases	$59.9M	EW Healthcare Partners, Johnson & Johnson Innovation 鈥� JJDC听&补尘辫;听	58/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Molecular Partners's competitors? Click to see the top ones

Molecular Partners has made no investments or acquisitions yet.

Here is the latest report on Molecular Partners's sector:

Free

Oncology - Sector Report

Edition: January, 2025 (79 Pages)

View

Media has covered Molecular Partners for a total of 19 events in the last 1 year, 15 of them have been about company updates and 2 about partnerships.